Pearson LK - Search Results

1

Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A.

Fleishaker JC, Pearson LK, Pearson PG, Wienkers LC, Hopkins NK, Peters GR. Fleishaker JC, et al. Among authors: pearson lk, pearson pg. J Clin Pharmacol. 1999 Mar;39(3):260-7. J Clin Pharmacol. 1999. PMID: 10073325 Clinical Trial.

2

Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.

Fleishaker JC, Pearson LK, Peters GR. Fleishaker JC, et al. Among authors: pearson lk. J Pharm Sci. 1995 Mar;84(3):292-4. doi: 10.1002/jps.2600840305. J Pharm Sci. 1995. PMID: 7616365

3

Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.

Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR. Fleishaker JC, et al. Among authors: pearson lk, pearson pg. J Pharmacol Exp Ther. 1996 May;277(2):991-8. J Pharmacol Exp Ther. 1996. PMID: 8627582 Clinical Trial.

4

Gender does not affect the degree of induction of tirilazad clearance by phenobarbital.

Fleishaker JC, Pearson LK, Peters GR. Fleishaker JC, et al. Among authors: pearson lk. Eur J Clin Pharmacol. 1996;50(1-2):139-45. doi: 10.1007/s002280050082. Eur J Clin Pharmacol. 1996. PMID: 8739825 Clinical Trial.

5

Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis.

Pearson LK, Fleishaker JC, Peters GR. Pearson LK, et al. Eur J Clin Pharmacol. 1996;50(4):299-304. doi: 10.1007/s002280050112. Eur J Clin Pharmacol. 1996. PMID: 8803523

6

Induction of tirilazad clearance by phenytoin.

Fleishaker JC, Pearson LK, Peters GR. Fleishaker JC, et al. Among authors: pearson lk. Biopharm Drug Dispos. 1998 Mar;19(2):91-6. doi: 10.1002/(sici)1099-081x(199803)19:2<91::aid-bdd78>3.0.co;2-t. Biopharm Drug Dispos. 1998. PMID: 9533108 Clinical Trial.

7

Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.

Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Moore TA, Peters GR. Fleishaker JC, et al. Among authors: pearson lk, pearson pg. J Pharmacol Exp Ther. 1998 Nov;287(2):591-7. J Pharmacol Exp Ther. 1998. PMID: 9808685 Clinical Trial.

8

Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F.

Fleishaker JC, Pearson LK, Knuth DW, Gomez-Mancilla B, Francom SF, McIntosh MJ, Freestone S, Azie NE. Fleishaker JC, et al. Among authors: pearson lk. Int J Clin Pharmacol Ther. 1999 Oct;37(10):487-92. Int J Clin Pharmacol Ther. 1999. PMID: 10543315 Clinical Trial.

9

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd. Slatter JG, et al. Among authors: pearson lk. Drug Metab Dispos. 2000 Apr;28(4):423-33. Drug Metab Dispos. 2000. PMID: 10725311 Clinical Trial.

10

Effect of acetylsalicylic acid and morphine on pressor responses produced by bradykinin.

Pearson L, Lang WJ. Pearson L, et al. Eur J Pharmacol. 1969 Apr;6(1):17-23. doi: 10.1016/0014-2999(69)90059-4. Eur J Pharmacol. 1969. PMID: 5784642 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters